The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neutrophil-to-lymphocyte ratio as a prognostic factor and its relationship to patient (pt) outcomes in the RAINBOW trial.
 
Kei Muro
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Parexel International (Inst); Parexel International (Inst); Parexel International (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Solasia Pharma (Inst); Solasia Pharma (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)
 
Jaffer A. Ajani
Honoraria - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck
Consulting or Advisory Role - American Cancer Society; American Cancer Society; American Cancer Society; American Cancer Society; BeiGene; BeiGene; BeiGene; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Insys Therapeutics; Insys Therapeutics; Insys Therapeutics; Insys Therapeutics; Merck; Merck; Merck; Merck; Vaccinogen; Vaccinogen; Vaccinogen; Vaccinogen
Research Funding - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Delta-Fly Pharma; Delta-Fly Pharma; Delta-Fly Pharma; Delta-Fly Pharma; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly; I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly; I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly; I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech; Genentech; Genentech; Genentech; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Novartis; Novartis; Novartis; Novartis
Research Funding - Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech; Genentech; Genentech; Genentech
 
Holly Knoderer
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Ran Wei
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Anindya Chatterjee
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Paolo Abada
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Atsushi Ohtsu
Employment - Celgene (I); Celgene (I); Celgene (I); Celgene (I)
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Ono Yakuhin; Ono Yakuhin; Ono Yakuhin; Ono Yakuhin; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb